Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure.

Trial Profile

Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Ordopidine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov
    • 03 Dec 2009 Official Title added as reported by ClinicalTrials.gov.
    • 03 Dec 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01023282).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top